Amarin Corp. PLC ADR (AMRN): Price and Financial Metrics

Amarin Corp. PLC ADR (AMRN): $1.02

0.02 (-1.92%)

POWR Rating

Component Grades








Add AMRN to Watchlist
Sign Up

Industry: Biotech




#42 of 361

in industry

AMRN Price/Volume Stats

Current price $1.02 52-week high $1.49
Prev. close $1.04 52-week low $0.65
Day low $1.01 Volume 547,900
Day high $1.05 Avg. volume 2,133,897
50-day MA $1.05 Dividend yield N/A
200-day MA $0.98 Market Cap 418.89M

AMRN Stock Price Chart Interactive Chart >

Amarin Corp. PLC ADR (AMRN) Company Bio

Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company was founded in 1989 and is based in Dublin, Ireland.

AMRN Latest News Stream

Event/Time News Detail
Loading, please wait...

AMRN Latest Social Stream

Loading social stream, please wait...

View Full AMRN Social Stream

Latest AMRN News From Around the Web

Below are the latest news stories about AMARIN CORP PLC that investors may wish to consider to help them evaluate AMRN as an investment opportunity.

13 Most Promising Small-Cap Stocks According to Analysts

In this piece, we will take a look at the 13 most promising small-cap stocks according to analysts. If you want to skip our overview of small cap investing and the latest stock market news, then you can take a look at the 5 Most Promising Small-Cap Stocks To Buy. Within the broader world of […]

Yahoo | December 27, 2023

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin’s president and chief executive officer, Patrick Holt, is scheduled to present at the conference on January 10, 2024. 42nd Annual J.P. Morgan Healthcare Conference (January 8th-11th, 2024; San Francisco, California) Date/Time: January 10, 2024, 4:30 p.m. ET/ 1:30 p.m. PST Webcast: https://jpmorga

Yahoo | December 11, 2023

Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

What Makes Amarin (AMRN) a New Buy Stock

Amarin (AMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 5, 2023

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease -- -- Findings Continue to Reinforce the Scientific Data and Clinical Use of VASCEPA®/VAZKEPA® to Reduce Cardiovascular Risk -- -- Results Presented Today at the American Heart Association (AHA) Scientific Sessions 2023 and Simultaneously Published in the European Heart Journal Open -- DUBLIN, Ireland

Yahoo | November 12, 2023

Read More 'AMRN' Stories Here

AMRN Price Returns

1-mo 18.19%
3-mo -13.56%
6-mo 34.33%
1-year -27.66%
3-year -79.92%
5-year -94.63%
YTD 17.24%
2023 -28.10%
2022 -64.09%
2021 -31.08%
2020 -77.19%
2019 57.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!